ACA
ENTA icon

Apis Capital Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Apis Capital Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$3.22M Sell
89,100
-43,500
-33% -$1.87M 4.45% 8
2015
Q2 		$5.96M Sell
132,600
-14,355
-10% -$558K 6.7% 4
2015
Q1 		$3.85M Buy
146,955
+3,645
+3% +$142K 5.26% 7
2014
Q4 		$7.29M Buy
+143,310
New +$6.42M 8.1% 2

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Apis Capital Advisors's ENTA Position: Q3 2015 in Review

Apis Capital Advisors reduced its Enanta Pharmaceuticals (ENTA) stake by 33% in Q3 2015, selling an estimated $1.87M and leaving 89,100 shares worth $3.22M. The position accounts for 4.45% of the portfolio, ranked #8.

Apis Capital Advisors first reported a position in ENTA in Q4 2014 and has held it in 4 quarters since. The position peaked at $7.29M in Q4 2014. 145 funds tracked by Wall St. Rank hold ENTA as of Q3 2015.

  • Apis Capital Advisors held 89,100 shares of Enanta Pharmaceuticals worth $3.22M as of Q3 2015.
  • Apis Capital Advisors sold 43,500 Enanta Pharmaceuticals shares in Q3 2015, an estimated $1.87M.
  • Enanta Pharmaceuticals made up 4.45% of Apis Capital Advisors's portfolio in Q3 2015, its #8 holding.
  • Apis Capital Advisors first reported a position in Enanta Pharmaceuticals in Q4 2014 and has held it in 4 quarters since.
  • Apis Capital Advisors's Enanta Pharmaceuticals position peaked at $7.29M in Q4 2014.
  • 145 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2015.

Based on Apis Capital Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.